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Knowing that infection of high-risk human papillomavirus (HPV) causes virtually all cervical cancer (CC), the long-term outcomes of
HPV infection, especially the absolute risk and time lapse of developing CC, are beyond the scope of ordinary follow-up study owing
to ethical concerns. The present study followed the natural history and long-term outcomes of HPV infection in a cohort of women
by national health insurance care and data linkage without additional disturbance. The status of cervical HPV infection was determined
in 1708 healthy women, aged 20–90 (median 43), enrolled from 10 hospitals in seven cities around the island country of Taiwan.
Records of consecutive Pap smear results and cancer reports of 108 cytology-negative, HPV-positive and 1202 cytology- and HPV-
negative women with no prior record of CC or abnormal cervical cytology were retrospectively analysed for a duration of up to 75
months (median 61 months). The cumulative incidences of high-grade squamous intraepithelial lesion (HSIL) and in situ/invasive
cancer in HPV-positive women were 5.6 and 3.7%, respectively, and those in HPV-negative women were 0.3 and 0%. After adjusting
for other risk factors, HPV-positive subjects had 24.9 (95% CI: 7.0–108.3; Po0.0001) folds of risk of developing HSIL or above
cervical neoplasia as compared to HPV-negative subjects, whereas risk for low-grade intraepithelial lesion and atypical squamous
cytology was not increased. The study showed that women with a prevalent infection of high-risk HPV had a 4% cumulative risk for
CC in 6 years, whereas those tested negative had little risk. The result supports an HPV test-orientated CC screening programme
with intervals of at least 5 years.
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The aetiological and universal roles of high-risk human papillo-
mavirus (HPV) infection in cervical carcinogenesis have been well
established. Primary and secondary preventive measures targeting
on the vaccination and detection of HPV have emerged as effective
public health strategies (Bulkmans et al, 2004; Kitchener et al,
2006; Mayrand et al, 2006; Wheeler, 2007). Before a wide
application of these preventive measures can be realised, an
accurate estimation of the long-term outcome of HPV infection is
critically in demand. A major but rarely studied outcome measure
is the absolute risk and sojourn time of developing cervical cancer
(CC) or its precursor in the presence of HPV infection (Sherman
et al, 2003). In the face of differences in host and environmental
factors, as well as the public and private health-care formats, the
natural history of HPV infection varied widely among different
populations. A regional follow-up of HPV infection is therefore
critically needed as the baseline epidemiological data for cost-
effectiveness modelling and policy making (Dasbach et al, 2006;
Newall et al, 2007; Wheeler, 2007).
Given the long and heterogeneous natural history of HPV
infection and the lack of a robust animal model or culture system,
studying the natural history of HPV infection typically requires a
cohort of long-term follow-up that is both labour intensive and
expensive. Following subjects beyond the precancer stage is
ethically not allowed. An alternative way is to utilize the registry
of medical records to follow subjects passively. Previous studies of
passive follow-up tested HPV infection serologically and retro-
spectively (Hinkula et al, 2004; Peto et al, 2004; Korodi et al, 2005;
Kjaer et al, 2006). In this prospective study, we conducted a
standard HPV DNA test and Pap smear and followed cervical
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sneoplasia by medical records linkage in a cohort of subjects who
were cared for by the national health insurance programme. A
6-year risk and sojourn time of occurrence of cervical neoplasia in
relation to HPV infection in a real world were unveiled.
MATERIALS AND METHODS
Study subjects and database linkage
On Mother’s Day (May 13) in 2000, a campaign of CC screening
including a single-visit Pap test and Hybrid Capture 2 (HC2;
Digene, Gaitherburg, MD, USA) HPV DNA testing was imple-
mented for mothers who had not been screened for at least 1 year
at 10 general hospitals from seven major cities around Taiwan: two
in Taipei metropolitan area, three in the north, one in the central
west, three in the southern west and one in the east of the island
(Figure 1). At the visit, standard demographic data, cancer-related
history and history relating to Pap smear interpretation were
recorded. The latter included menstrual and pregnant history,
contraceptive method, past or present history of cervical neoplasia
and previous history of hysterectomy or radiation. Part of the
cervical scraping was sent for HPV test, and the subjects were
informed of the test results. A total of 1708 women who agreed to
the screening activity and had a successful HPV DNA test detected
by HC2 were enrolled. All subjects were cared for by the National
Health Insurance system, which provides comprehensive health
services, including preventive and medical services, prescription
drugs and others, with good accessibility at reasonable cost
(Lu and Hsiao, 2003). To reveal the outcomes of HPV infection in
the real world, enrolled subjects were left undisturbed and the end
points of cervical neoplasia were collected through the national
database of Pap smear and cancer registry.
A schematic overview of the study design and case outcomes
was shown in Figure 2. One hundred and twenty subjects refused
the follow-up and did not provide their personal identification
number (ID). The remaining 1588 subjects were passively followed
by linking their ID to the Taiwan Cervical Cytology Screening and
Histology Database and to the Taiwan Cancer Registry in August
2006. This data linking analysis was approved by the Bureau of
Health Promotion, Department of Health, Taiwan. Among the 1588
subjects, 288 having no record of Pap smear or cancer registry data
during the follow-up period were excluded. Also excluded were 14
subjects who had records of abnormal Pap smear test results
(including Atypia or more severe results) or CC prior to 13 May
2000, and five subjects having CC detected on 13 May 2000. Pap
smear and cancer registry data of the remaining 1310 eligible
subjects were analysed. Their median age was 43 (ranged 23–80)
years.
Pap smear follow-up
The National Health Insurance of Taiwan provides annual Pap
smear screening for women aged 30 or above since 1995 (Koong
et al, 2006). The Pap smear screening programme included a
quality control monitoring and training system covering the
physician, public health nurses, cytologists and cytotechnicians.
Taoyan
Min-Sheng Hospital (N=197)
Li-Shin Hospital (N=132)
Taipei
Taipei Veterans General Hospital (N=164)
Taipei Municipal Wan-Fang Hospital (N=158)
Hsinchu
Ton-YEn Hospital (N=200)
Taichung
Taichung Veterns General Hospital (N=287)
Tainan
Chi Mei Medical Center (N=100)
Kuo General Hospital (N=97)
Kaohsiung
Chung-Ho Memorial Hospital (N=174)
Hualien
Mennonite Christian Hospital (N=199)
Figure 1 Locations of study sites. The number of study sites was proportional to the population density in the five major areas: five in the north, four in
the south and one each in the middle west and the east part of Taiwan.
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sThe results of Pap smears and cervical biopsies were recorded in
the National Cervical Cytology and Histology Registry as a
comprehensive and confidential database. A 3-year screening rate
increased from 14.5% in 1995 to 53.8% in 2005 (Department of
Health Executive Yuan Taiwan, 2005). The cytology report
followed the Bethesda System and shifted to its new version in
2002 (Solomon et al, 2002). In the analysis, we reclassified the
cytology results into Normal (including ‘normal’ and ‘benign
reactive change’), Atypia (including ‘atypical squamous cells of
undetermined significance’ or ‘atypical glandular cells of un-
determined significance’), low grade squamous intraepithelial
lesion (LSIL), high-grade squamous intraepithelial lesion (HSIL)
(excluding carcinoma in situ (CIS)) and CIS/adenocarcinoma
in situ (AIS)/CC. The most severe cytology results occurring
during the follow-up period were counted, and the lag time was
counted between the date of enrolment and the date of occurrence
of the most severe abnormal cytology.
Follow-up by cancer registry
The Taiwan Cancer Registry was established in 1970. The data were
input from the medical delivery system consisting of one cancer
hospital, 18 medical centres and hundreds of regional and district
general hospitals. In 1995, 81% of the reported cancers were
confirmed by pathological examinations, 13% by imaging diag-
nosis and 6% by other methods (Chen et al, 2002). Since the
implementation of the National Health Insurance in 1995, 97
and 99% of the total population have been enrolled by 2001
(Lu and Hsiao, 2003) and 2007, respectively. The reporting rate of
the Taiwan Cancer Registry is one of the highest in the world. The
ID of the eligible subjects was linked to the registry and looked for
the occurrence of CC with the ICD9 disease code of 180 during the
period between May 2000 and August 2006. Cervical cancer
records before May 2000 were also surveyed to exclude the
ineligible subjects. There were nine cancers on record between
May 2000 and August 2006. Among them, five cancers occurred on
enrolment, which were not possibly a consequence of the recent
HPV infection, and were excluded. There was one metastatic
cancer from the colon, which was also excluded. The remaining
three were two CIS and one invasive cancer of the uterine cervix,
which occurred at the 28th, 32nd and 34th months, respectively,
after enrolment.
HPV detection
Hybrid Capture 2 high-risk HPV DNA test was conducted. Cervical
scrapings were collected by using the cytobrush and transfer
medium provided by the manufacturer. The same cytobrush was
used for Pap smear before dipping into the transfer medium for
HPV test. Hybrid Capture 2 used RNA probes specific for 13
cancer-associated HPV types. The DNA–RNA hybrids were
captured and detected by reporter molecule-labelled antibodies
as described before (Sun et al, 2001). Coefficients of variation of
the triplicate tests of both the positive (50fg or 5000 copies of
HPV-16 DNA) and the negative (100ng of carrier DNA) controls
(n¼3) were less than 5%, respectively, and the ratio of positive
mean to negative mean was more than 3.0.
Human papillomavirus genotyping in HC2-positive cervical
scrapings was determined by consensus PCR and reverse blot
hybridisation as previously described (Huang et al, 2006; Lin et al,
2007). Briefly, the SPF1/GP6 consensus primers were used to
amplify a fragment of approximately 184bp in the L1 open reading
frame. The PCR products were then hybridised with an Easychip
HPV Blot (King Car, Yilan, Taiwan) that included 39 types of HPV
(types 6, 11, 16, 18, 26, 31, 32, 33, 35, 37, 39, 42, 43, 44, 45, 51, 52,
53, 54, 55, 56, 58, 59, 61, 62, 66, 67, 68, 69, 70, 72, 74, 82, CP8061,
CP8304, L1AE5, MM4, MM7 and MM8) of oligonucleotide probes
and were visualised by alkaline phosphatase conjugation and
biotinylated antibodies (Huang et al, 2006; Lai et al, 2007).
Statistical analysis
STATA version 8 was used for data analysis. w
2 test was used to
assess the association of categorical variables and Student’s t-test
was used to assess continuous variables. Kaplan–Meier plots were
used to compare the nonoccurrence of cervical neoplasia of
participants with or without HPV infection. Log-rank test was
used for comparison of the nonoccurrence curves between
HPV-positive and HPV-negative subjects. By use of the Cox
proportional hazards model, multivariate analysis was performed
1708 women with HCII in 13 May 2000
120 (7.02%) failed the data
linkage
258 (16.25%) without any registered
data record between 1995 and 2006
1330 (83.75%) had at least one
registered data between 1995 and 2006
14 had prior record
of cervical cancer
or abnormal Pap
smear (atypia or
 above) before
13 may 2000
One had a
metastatic cancer
to uterine cervix
Five had
prevalent cervical
cancer
1310 had no prior record of cervical
abnormalities and had at least one
follow up record during the period
of 1 January 2001 to 31 July 2006 
Normal
N=1251
ASC
N=32
LSIL
N=13
HSIL
or CIS
N=12
AIS or CC
N=2
1588 linked to National Cervical
Cytology and Histology Registry and
Cancer Registry
Figure 2 A schematic overview of the data linkage and follow-up outcomes. After exclusion of ineligible subjects, 1310 women fulfilled the follow-up
criteria and the outcome classification was given.
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sto determine the independent impact of HPV infection on survival.
Failure events were defined as the occurrences of (1) Atypia, (2)
LSIL and (3) HSIL or above neoplasia. For all statistical tests, the
level of significance was set at 0.05.
RESULTS
All the subjects studied had a normal Pap smear result at
enrolment on 13 May 2000 and at least one Pap smear or cancer
registry entry data during the follow-up period till 31 August 2006.
As shown in Table 1, the duration of follow-up did not differ
between HPV-positive and HPV-negative subjects (57.80±0.39 vs
59.52±1.21 months) (mean±s.e.m.). As expected, HPV-positive
subjects had a slightly shorter follow-up interval (24.47±1.45
months) than the HPV-negative (27.38±0.43 months) subjects
(P¼0.06). The average number of follow-up was slightly higher in
HPV-positive groups than in HPV-negative groups (3.15±0.23
vs 2.79±0.04). When stratified by follow-up outcomes, the follow-
up intervals did not differ between the two groups (Table 1).
In the screened population, which had a median age of 43 years
(ranging from 20 to 90), the prevalence of HPV infection was
8.24% (108/1310). The rate tended to increase with age, from 8.08%
in age 30–40 years to 10.0% in age over 60 years, but without
statistical significance. Among different geographic regions,
participants living in Taoyan and Hsinchu had a slightly but
insignificantly higher HPV prevalence (9.64%) as compared to
other regions (6.37–8.66%) (Table 2).
The records of consecutive Pap smear results and cancer reports
of 108 cytology-negative, HPV-positive and 1202 cytology- and
HPV-negative women were followed for a median duration of 61
months. In the meanwhile, there were five prevalent cases of CC,
who were all HPV-positive, being excluded from the follow-up.
The status of HPV infection on enrolment mattered greatly to the
outcomes of follow-up. In HPV-positive subjects (n¼108),
12% developed cervical neoplasia, whereas only 3.8% of HPV-
negative subjects (n¼1202) did so. The major difference was the
occurrence rate of HSIL or above neoplasia, which was 9.25% in
the HPV-positive group and 0.14% in the HPV-negative group.
All the four subjects with follow-up outcomes of CIS (n¼2), AIS
or CC were HPV-positive on enrolment (Table 3). When
comparing different follow-up outcomes, the HPV prevalence
at enrolment was significantly higher in the CIS/AIS/CC outcome
group (100%) than in the HSIL outcome (60.0%), Atypia outcome
(9.4%), Normal outcome (7.6%) and LSIL outcome (0%) groups
(Po0.0001, Table 3). As shown in Figure 3, during a maximal
follow-up of 74 months, the occurrence of HSIL or above cervical
neoplasia was significantly higher in the HPV-positive subjects
than in the HPV-negative subjects, with an adjusted hazard ratio of
24.9 (7.01–108.27) (Po0.0001). Table 4 summarises the incidence
and hazard ratio of different follow-up outcomes. Compared to
HPV-negative subjects, the incidence of HSIL or above neoplasia
in HPV-positive subjects was significantly higher (0.0194 vs
0.0007), but this was not true in the Atypia and LSIL groups.
Figure 3 shows the Kaplan–Meier estimates of the occurrence
of HSIL or above cervical neoplasia during the follow-up. The
adjusted hazard ratio for HPV-positive vs HPV-negative subjects
was 24.9 (7.01–108.27) (Po0.0001). The cumulative risk for HSIL
or above cervical neoplasia in HPV-positive subjects was 3.88% in
4 years, 4.88% in 5 years and 10.0% in 6 years. For HPV-negative
subjects, the cumulative risks were 0.086, 0.26 and 0.34% in 4,
5 and 6 years, respectively.
Table 1 Durations, intervals and outcomes of Pap smear follow-up in HPV-positive and HPV-negative subjects
HPV-negative subjects HPV-positive subjects
Follow-up outcome
a No FU duration
b (month) FU interval (month) No FU duration
b (month) FU interval (month) P-value
c
Normal 1156 58.06±0.39 27.83±0.44 95 59.57±1.27 25.25±1.46 P¼0.10
Atypia 29 50.53±3.42 17.93±2.41 2 55.31±9.46 9.76±1.41 P¼0.01
LSIL 13 51.99±3.76 11.51±1.14 0 — — —
HSIL or above
d 4 55.08±6.32 17.53±4.46 7 60.59±4.90 20.15±8.30 P¼0.83
All 1202 57.80±0.39 27.38±0.43 105 59.52±1.21 24.47±1.45 P¼0.06
Abbreviations: HPV¼human papillomavirus; HSIL¼high-grade squamous intraepithelial lesion.
aSee Materials and Methods for the definitions.
bIn outcomes other than Normal,
the follow-up (FU) duration equals to the time to occurrence.
cComparison of follow-up intervals between HPV-positive and HPV-negative subjects. P-value for Student’s t-test.
dThe three cancer victims identified by Cancer Registry were not included.
Table 2 Status of high-risk HPV infection on enrolment and outcome of follow-up
Total subject (n¼1310) HPV-positive (n¼108) HPV prevalence % (95% CI) v
2 (P-value)
Age category
Ageo30 55 5 9.09 (3.02–19.95) w
2¼0.22 (P¼0.99)
30pageo40 421 34 8.08 (5.66–11.1)
40pageo50 503 40 7.95 (5.74–10.67)
50pageo60 214 17 7.94 (4.69–12.41)
60page 100 10 10.00 (4.90–17.62)
Missing 17 2 11.76 (1.46–36.44)
Area of residence
Taipei 277 24 8.66 (5.63–12.61) w
2¼2.56 (P¼0.63)
Taoyuan and Hsinchu 394 38 9.64 (6.91–12.24)
Taichung 215 18 8.37 (5.03–12.91)
Tainan and Kaohsiung 267 18 6.74 (4.04–10.44)
Hualien 157 10 6.37 (3.1–11.4)
Abbreviations: HPV¼human papillomavirus.
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sTable 5 shows the follow-up results of subjects infected with
different HPV types. Although 27 different high-risk and low-risk
HPV types were found in subjects with Normal outcome, only limited
high-risk types such as types 16, 18, 31, 51, 58, 59 and 70 were found
in subjects with outcomes of HSIL or above cervical neoplasia. Owing
to small sample sizes in each HPV type stratum, no significant
differences were noted among different HPV types or groups.
1.00
0.75
0.00
HPV-negative
HPV (–) At risk 1160
0
105
0
1142
0
104
0
1062
0
96
4
905
1
81
4
617
2
61
5
132
4
9
10
Failure
Failure
At risk HPV (+)
HPV-positive
02 0 4 0
Months
Number at risk or
failure at time (months)
0 2 43 6 4 86 07 6
60 80
Figure 3 Kaplan–Meier estimates of HSIL or above outcome in HPV-
positive and HPV-negative subjects. Failure was defined as the occurrence
of HSIL or above cervical neoplasia. The adjusted hazard ratio was 24.9
(7.01–108.27) (Po0.0001). HPV¼human papillomavirus; HSIL¼high-
grade squamous intraepithelial lesion.
Table 3 Outcomes of follow-up and the HPV status on enrolment
Total
HPV ( )
n¼1202
HPV (+)
n¼108
HPV
prevalence at
enrolment
(%)
Follow-up results
a
Normal 1251 1156 (96.2%) 95 (88.0%) 7.6 (6.9–13.0) w
2¼81.85
Atypia 32 29 (2.4%) 3 (2.8%) 9.4 (2.0–25.0) (Po0.0001)
LSIL 13 13 (1.1%) 0 (0.0%) 0.0 (0.0–24.7)
HSIL 10 4 (0.3%) 6 (5.6%) 60.0 (26.2–87.8)
CIS/AIS/CC 4 0 (0.0%) 4 (3.7%) 100.0 (39.8–100.0)
All 1310 1202 (100%) 108 (100%) 8.2 (6.81–9.9)
Abbreviations: CC¼cervical cancer; HPV¼human papillomavirus; HSIL¼high-
grade squamous intraepithelial lesion.
aSee Materials and Methods for the definition of
the categories.
Table 4 Incidence rate and hazard ratio of cervical neoplasia in relation to the HPV status at enrolment
HSIL or above
a Atypia
a LSIL
a
HPV ( ) HPV (+) Total HPV ( ) HPV (+) Total HPV ( ) HPV (+) Total
Incidence case 4 10 14 29 2 35 13 0 13
Follow-up time (person-year) 5623 515 6138 5732 498 6230 5660 473 6133
6-year cumulative incidence 0.0034 0.1000 0.0111 0.0247 0.0310 0.0277 0.0111 — 0.0111
Incidence rate 0.0007 0.0194 0.0022 0.0051 0.0060 0.0051 0.0023 — 0.0021
Incidence rate ratio (95% CI) 27.30 1.19 —
(7.87–119.23) (0.23–3.84)
Hazard ratio (95% CI) 1.0 26.29 1.0 1.27
(8.24–83.86)* (0.39–4.17)
Adjusted hazard ratio
b (95% CI) 1.0 24.89 1.0 0.85 —
(7.01–108.27)* (0.20–3.56)
P-value for log-rank test Po0.0001 P¼0.69
Abbreviations: HPV¼human papillomavirus; HSIL¼high-grade squamous intraepithelial lesion. *Po0.0001.
aSee Materials and Methods for the definitions.
bAge, area of
residence and follow-up interval were adjusted using the Cox proportion hazard model.
Table 5 The distribution of HPV genotypes in different follow-up
outcomes among the HC2-positive subjects
Pap normal
subjects Atypia LSIL
HSIL or
above
HPV on enrolment No. (%) No. (%) No. (%) No. (%)
Negative 1156 (92.41) 29 (90.63) 13 (100.0) 4 (28.57)
Positive 95 (7.59) 3 (9.38) 0 (0.00) 10 (71.43)
HPV type
6 1 (0.87) 1 (12.5) — —
11 3 (2.61) 1 (12.5) — —
16 10 (8.7) — — 4 (28.57)
18 9 (7.83) 1 (12.5) — 2 (14.29)
31 2 (1.74) 1 (12.5) — 2 (14.29)
32 1 (0.87) — — —
33 4 (3.48) — — —
35 1 (0.87) — — —
39 3 (2.61) — — —
44 1 (0.87) — — —
45 — 1 (12.5) — —
51 3 (2.61) 1 (12.5) — 1 (7.14)
52 10 (8.7) 1 (12.5) — —
54 2 (1.74) — — —
56 5 (4.35) — — —
58 7 (6.09) — — 2 (14.29)
59 1 (0.87) 1 (12.5) — 2 (14.29)
61 1 (0.87) — — —
62 3 (2.61) — — —
66 5 (4.35) — — —
68 2 (1.74) — — —
70 11 (9.57) — — 1 (7.14)
74 1 (0.87) — — —
87 1 (0.87) — — —
L1AE 1 (0.87) — — —
MM4 1 (0.87) — — —
MM8 1 (0.87) — — —
PCR result negative 25 (21.74) — — —
Abbreviations: HPV¼human papillomavirus; HSIL¼high-grade squamous intrae-
pithelial lesion.
Long-term outcomes of HPV infection
Y-K Huang et al
867
British Journal of Cancer (2008) 98(5), 863–869 & 2008 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sDISCUSSION
A nonintervention, passive follow-up of HPV-infected subjects was
conducted in this study as a way to explore the natural history of
the infection in the real world of a universal health insurance care
system. The absolute risks of the occurrence of cervical neoplasia
were obtained in infected and noninfected subjects. The prevalence
of high-risk HPV infection determined by HC2 (8.2%) was similar
to that in other reports from the same population (Liaw et al, 1995;
Department of Health Executive Yuan Taiwan, 2005; Sun et al,
2005). HPV prevalence did not differ among the seven areas
studied in this island country. Besides, the results of Pap smear
screening including ages (median 43 years, ranged from 20 to 90)
and distributions of abnormal cytology (2.4, 1.0 and 0.8% of
Atypia, LSIL and HSIL or above, respectively) did not differ from
those reported in the National Registry (Department of Health
Executive Yuan Taiwan, 2005), indicating a good representation of
this cohort to this small island country.
Passive follow-up of cervical neoplasia requires a well-estab-
lished public or private health-care system with long-term and
consistent coverage of the target population (Castle et al, 2002) and
comprehensive databases. The possible limitations of this study
include uncontrolled follow-up intervals, low coverage rate and
insufficient disease assessment. Although an annual screening
policy was conducted in this country, the 3-year coverage rate was
55% and the screening interval of this cohort was 24 months,
which was shorter than other cohorts conducted in the UK (the
Manchester cohort) (Peto et al, 2004) and Denmark (Kjaer et al,
2006) where screening intervals were typically 3–5 years. As an
augmentation to this limitation, the national cancer registry
database, which records all cancer cases from the diagnosing
hospitals, was also applied to identify prevalent and incident CIS
and CC that may be missed by Pap smear screening or diagnosed
without screening. As subjects were informed of the result of the
HPV test, a positive test result may motivate more frequent,
regular follow-up visits that may be biased towards a higher
detection rate of cervical neoplasia. The follow-up intervals in the
HPV-positive subjects were somewhat shorter than in the HPV-
negative subjects (24.5 vs 27.4 months, P¼0.06). However, after
exclusion of subjects with neoplastic outcomes, those with Normal
outcome had similar follow-up intervals in the HPV-positive and
HPV-negative groups (25.3 vs 27.9 months, P¼0.1).
Previous long-term follow-up studies of the outcomes of HPV
infection were limited (Rozendaal et al, 2000; Schlecht et al, 2001;
Castle et al, 2002; Peto et al, 2004; Kjaer et al, 2006). Early studies
used the insensitive cytology but not DNA test as the diagnostic
criteria (Nash et al, 1987; Syrjanen et al, 1992). Some studies were
focused on young women whose HSIL were less likely to progress
to more severe neoplasia (Koutsky et al, 1992; Woodman et al,
2001). This study aimed to elucidate the long-term outcome of the
population at risk for CC. Mature women were followed for the
occurrence of CC and its precursor for up to 75 months. The 4-, 5-
and 6-year cumulative incidences of HSIL or above neoplasia were
3.9, 4.9 and 10%, respectively, in HPV-positive women, as
compared to 0.09, 0.26 and 0.34% in the HPV-negative women.
A trend of increasing cumulative risk along the follow-up period
beyond 4 years was noted, indicating the need for longer follow-up
for the severe outcomes. A British cohort of passive follow-up also
showed rising cumulative risk of CIN3 or cancer in HPV-positive
women, reaching 28% by 14 years (1). HPV-positive women
followed by the Danish Pathology Data Bank showed a 10-year risk
for CIN3 or cancer of 13.6 and 21% for young (22–32 years) and
old (40–50 years) women, respectively. As a comparison, a lower
5-year cumulative incidence of HSIL or above neoplasia was noted
in the Portland cohort (Castle et al, 2002), and a much higher
figure (about 25 vs 5%) was noted in the Brazil cohort (Schlecht
et al, 2001). Although the status of risk factors other than HPV
infection, such as the environmental (such as smoking and other
genital infections) (Koskela et al, 2000; Smith et al, 2002) and
genetic susceptibility (Caucasian vs Chinese) to cervical carcino-
genesis can be different among cohorts, the accessibility and extent
of medical interventions, such as Pap smear, cervical biopsy and
local treatments, may be the key differences among the settings.
The subjects in this cohort were completely undisturbed after a
single visit for Pap smear and HPV testing. The results thus figure
the real natural history of HPV infection in the population in
Taiwan.
In contrast to the occurrence of HSIL and cancer, which was
highly associated with HPV infection at enrolment, in this study and
that of the Manchester cohort (Peto et al, 2004), the occurrence of
LSIL was found to be unrelated to the initial HPV status. LSIL is
known to be an immediate and transient disease of HPV infection.
Given a follow-up interval of 24 months, most of the HPV-related
LSIL that was missed by cytology at enrolment may have been
regressed at the first follow-up. Meanwhile, none of the subjects
tested negative for both cytology and high-risk HPV on enrolment
developed CIS or invasive cancer during the 6-year follow-up.
Women who are HPV-negative bear little risk for CC in this study.
This supports a focused cytology screening of HPV-infected women.
In the current socio-economic setting in Taiwan, an HPV test-
orientated screening is suggested. Only HPV-positive women have to
be screened annually. Human papillomavirus-negative women may
safely extend their screening interval to 5 years at least.
ACKNOWLEDGEMENTS
We are grateful to Dr Zuo-Lu Wu, Dr Mao-Chiao Chiang and Dr
Cheng-Chiun Yang of Min-Sheng hospital; Dr Yun-Long Tang and
Dr De-Ming Chao of Li-Shin hospital; Dr Jung-Chang Chang of
Kuo general hospital; Dr Ming-Ting Chung of Chi Mei medical
center; Dr Shing-Shiou Yuan of Chung-Ho memorial hospital;
Dr Chih-Hung Lien and Dr Chang-Yun Chiang of Mennonite
Christian hospital, Hualien for their work of case recruitment; to
the Bureau Health Promotion, Department of Health, Taiwan, and
to the personnel of Taiwan Cervical Cytology Screening and
Histology Database and Taiwan Cancer Registry. We are grateful to
Mr Chen-Ying Chien, Bio-Check Laboratories LTD for supplying
the HC2 assay. This study was supported by National Science
Council, Taiwan, ROC (Grant numbers: NSC 94-2314-B-016-039,
NSC 95-2314-B-303-008).
REFERENCES
Bulkmans NW, Rozendaal L, Snijders PJ, Voorhorst FJ, Boeke AJ,
Zandwijken GR, van Kemenade FJ, Verheijen RH, Groningen K, Boon
ME, Keuning HJ, van Ballegooijen M, van den Brule AJ, Meijer CJ (2004)
POBASCAM, a population-based randomized controlled trial for
implementation of high-risk HPV testing in cervical screening: design,
methods and baseline data of 44,102 women. Int J Cancer 110: 94–101
Castle PE, Wacholder S, Sherman ME, Lorincz AT, Glass AG, Scott DR,
Rush BB, Demuth F, Schiffman M (2002) Absolute risk of a subsequent
abnormal pap among oncogenic human papillomavirus DNA-positive,
cytologically negative women. Cancer 95: 2145–2151
Chen CJ, You SL, Lin LH, Hsu WL, Yang YW (2002) Cancer epidemiology
and control in Taiwan: a brief review. Jpn J Clin Oncol 32: S66–S81
Dasbach EJ, Elbasha EH, Insinga RP (2006) Mathematical models
for predicting the epidemiologic and economic impact of vaccination
against human papillomavirus infection and disease. Epidemiol Rev 28:
88–100
Long-term outcomes of HPV infection
Y-K Huang et al
868
British Journal of Cancer (2008) 98(5), 863–869 & 2008 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sDepartment of Health Executive Yuan Taiwan. Pap Smear Screening
Registry System Annual Report Republic of China, 2004. Department of
Health Executive Yuan. 1-111. Taiwan: Pap Smear Screening Registry
System Annual Report Republic of China, 2005 Ref Type: Report
Hinkula M, Pukkala E, Kyyronen P, Laukkanen P, Koskela P, Paavonen J,
Lehtinen M, Kauppila A (2004) A population-based study on the risk of
cervical cancer and cervical intraepithelial neoplasia among grand
multiparous women in Finland. Br J Cancer 90: 1025–1029
Huang SL, Chao A, Hsueh S, Chao FY, Huang CC, Yang JE, Lin CY, Yan CC,
Chou HH, Huang KG, Huang HJ, Wu TI, Tseng MJ, Qiu JT, Lin CT,
Chang TC, Lai CH (2006) Comparison between the Hybrid Capture II
Test and an SPF1/GP6+ PCR-based assay for detection of
human papillomavirus DNA in cervical swab samples. J Clin Microbiol
44: 1733–1739
Kitchener HC, Almonte M, Wheeler P, Desai M, Gilham C, Bailey A,
Sargent A, Peto J (2006) HPV testing in routine cervical screening: cross
sectional data from the ARTISTIC trial. Br J Cancer 95: 56–61
Kjaer S, Hogdall E, Frederiksen K, Munk C, van den BA, Svare E, Meijer C,
Lorincz A, Iftner T (2006) The absolute risk of cervical abnormalities in
high-risk human papillomavirus-positive, cytologically normal women
over a 10-year period. Cancer Res 66: 10630–10636
Koong SL, Yen AM, Chen TH (2006) Efficacy and cost-effectiveness of
nationwide cervical cancer screening in Taiwan. J Med Screen 13:
S44–S47
Korodi Z, Dillner J, Jellum E, Lumme S, Hallmans G, Thoresen S,
Hakulinen T, Stattin P, Luostarinen T, Lehtinen M, Hakama M (2005)
Human papillomavirus 16, 18, and 33 infections and risk of prostate
cancer: a Nordic nested case–control study. Cancer Epidemiol Biomar-
kers Prev 14: 2952–2955
Koskela P, Anttila T, Bjorge T, Brunsvig A, Dillner J, Hakama M,
Hakulinen T, Jellum E, Lehtinen M, Lenner P, Luostarinen T, Pukkala E,
Saikku P, Thoresen S, Youngman L, Paavonen J (2000) Chlamydia
trachomatis infection as a risk factor for invasive cervical cancer. Int J
Cancer 85: 35–39
Koutsky LA, Holmes KK, Critchlow CW, Stevens CE, Paavonen J,
Beckmann AM, DeRouen TA, Galloway DA, Vernon D, Kiviat NB
(1992) A cohort study of the risk of cervical intraepithelial neoplasia
grade 2 or 3 in relation to papillomavirus infection. N Engl J Med 327:
1272–1278
Lai CH, Huang HJ, Hsueh S, Chao A, Lin CT, Huang SL, Chao FY, Qiu JT,
Hong JH, Chou HH, Chang TC, Chang CJ (2007) Human papillomavirus
genotype in cervical cancer: A population-based study. Int J Cancer 120:
1999–2006
Liaw KL, Hsing AW, Chen CJ, Schiffman MH, Zhang TY, Hsieh CY,
Greer CE, You SL, Huang TW, Wu TC (1995) Human papillomavirus and
cervical neoplasia: a case–control study in Taiwan. Int J Cancer 62:
565–571
Lin CY, Chen HC, Lin RW, You SL, You CM, Chuang LC, Pan MH, Lee MH,
Chou YC, Chen CJ (2007) Quality assurance of genotyping array for
detection and typing of human papillomavirus. J Virol Methods 140: 1–9
Lu JFR, Hsiao WC (2003) Does universal health insurance make health care
unaffordable? Lessons from Taiwan. Health Aff 22: 77–88
Mayrand MH, Duarte-Franco E, Coutlee F, Rodrigues I, Walter SD,
Ratnam S, Franco EL (2006) Randomized controlled trial of human
papillomavirus testing versus Pap cytology in the primary screening for
cervical cancer precursors: design, methods and preliminary accrual
results of the Canadian cervical cancer screening trial (CCCaST). Int J
Cancer 119: 615–623
Nash JD, Burke TW, Hoskins WJ (1987) Biologic course of cervical human
papillomavirus infection. Obstet Gynecol 69: 160–162
Newall AT, Beutels P, Wood JG, Edmunds WJ, Macintyre CR (2007)
Cost-effectiveness analyses of human papillomavirus vaccination. Lancet
Infect Dis 7: 289–296
Peto J, Gilham C, Deacon J, Taylor C, Evans C, Binns W, Haywood M,
Elanko N, Coleman D, Yule R, Desai M (2004) Cervical HPV infection
and neoplasia in a large population-based prospective study: the
Manchester cohort. Br J Cancer 91: 942–953
Rozendaal L, Westerga J, van der Linden JC, Walboomers JM, Voorhorst FJ,
Risse EK, Boon ME, Meijer CJ (2000) PCR based high risk HPV testing is
superior to neural network based screening for predicting incident CIN
III in women with normal cytology and borderline changes. J Clin Pathol
53: 606–611
Schlecht NF, Kulaga S, Robitaille J, Ferreira S, Santos M, Miyamura RA,
Duarte-Franco E, Rohan TE, Ferenczy A, Villa LL, Franco EL (2001)
Persistent human papillomavirus infection as a predictor of cervical
intraepithelial neoplasia. JAMA 286: 3106–3114
Sherman ME, Lorincz AT, Scott DR, Wacholder S, Castle PE, Glass AG,
Mielzynska-Lohnas I, Rush BB, Schiffman M (2003) Baseline cytology,
human papillomavirus testing, and risk for cervical neoplasia: a 10-year
cohort analysis. J Natl Cancer Inst 95: 46–52
Smith JS, Herrero R, Bosetti C, Munoz N, Bosch FX, Eluf-Neto J,
Castellsague X, Meijer CJ, Van den Brule AJ, Franceschi S, Ashley R
(2002) Herpes simplex virus-2 as a human papillomavirus cofactor in the
etiology of invasive cervical cancer. J Natl Cancer Inst 94: 1604–1613
Solomon D, Davey D, Kurman R, Moriarty A, O’Connor D, Prey M, Raab S,
Sherman M, Wilbur D, Wright Jr T, Young N (2002) The 2001 Bethesda
System: terminology for reporting results of cervical cytology. JAMA 287:
2114–2119
Sun CA, Hsiung CA, Lai CH, Chen CA, Chou CY, Ho CM, Twu NF,
Feng WL, Chuang MH, Hsieh CY, Chu TY (2005) Epidemiologic
correlates of cervical human papillomavirus prevalence in women with
abnormal Pap smear tests: a Taiwan Cooperative Oncology Group
(TCOG) study. J Med Virol 77: 273–281
Sun CA, Lai HC, Chang CC, Neih S, Yu CP, Chu TY (2001) The significance
of human papillomavirus viral load in prediction of histologic severity
and size of squamous intraepithelial lesions of uterine cervix. Gynecol
Oncol 83: 95–99
Syrjanen K, Kataja V, Yliskoski M, Chang F, Syrjanen S, Saarikoski S (1992)
Natural history of cervical human papillomavirus lesions does not
substantiate the biologic relevance of the Bethesda system. Obstet
Gynecol 79: 675–682
Wheeler CM (2007) Advances in primary and secondary interventions for
cervical cancer: human papillomavirus prophylactic vaccines and testing.
Nat Clin Pract Oncol 4: 224–235
Woodman CB, Collins S, Winter H, Bailey A, Ellis J, Prior P, Yates M,
Rollason TP, Young LS (2001) Natural history of cervical human
papillomavirus infection in young women: a longitudinal cohort study.
Lancet 357: 1831–1836
Long-term outcomes of HPV infection
Y-K Huang et al
869
British Journal of Cancer (2008) 98(5), 863–869 & 2008 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
s